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Experimental Aortic Valve Stenosis in Rabbits
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OBJECTIVES We studied a known rabbit model of atherosclerosis to assess the effect of a hypercholester-
olemic diet on aortic valve morphology and function. We also evaluated the effects of the
combination of this diet with vitamin D supplements on the development of the disease and
the occurrence of valve calcification.
BACKGROUND Aortic valve stenosis (AVS) is the most common valvular heart disease. Recent observations
have suggested a link between atherosclerosis and the development of AVS. However, until
now, there has been no solid direct proof of this potential link.
METHODS Rabbits were divided in three groups: 1) no treatment; 2) cholesterol-enriched diet (0.5%
cholesterol); and 3) cholesterol-enriched diet plus vitamin D2 (50,000 IU/day). Echocardio-
graphic assessment of the aortic valve was done at baseline and after 12 weeks of treatment.
The aortic valve area (AVA) and maximal and mean transvalvular gradients were recorded
and compared over time.
RESULTS Control animals displayed no abnormalities of the aortic valve. Despite important increases
in blood total cholesterol levels, animals in group 2 did not develop any significant functional
aortic valve abnormality over 12 weeks. However, eight of 10 of the animals in group 3
developed a significant decrease in AVA (p 0.004) and significant increases in transvalvular
gradients (p  0.003).
CONCLUSIONS This study supports a potential link between atherosclerosis and the development of AVS.
The differences noted between hypercholesterolemic animals with or without vitamin D2
supplementation imply a significant role of calcium in the development of AVS, meriting
further attention. (J Am Coll Cardiol 2003;41:1211–7) © 2003 by the American College
of Cardiology Foundation
Aortic valve stenosis (AVS) is the most common valvular
heart disease in Western countries. Because AVS was
always considered to be simply a degenerative disease of the
valve, virtually no attention was given to its potential
medical treatment other than surgical replacement of the
valve in severe symptomatic cases. However, many recent
observations have suggested a link between the pathophys-
iology of development of AVS and atherosclerotic disease.
In cohort studies, many traditional atherosclerotic risk
factors have been associated with an increasing prevalence of
AVS (1–6). Therefore, many investigators now center their
efforts on the hypothesis of an atherosclerosis–AVS link.
Animal models of AVS have been developed in the past,
but all of those models implied surgical manipulation of the
aortic valve, per se, or banding of the ascending aorta. None
of these invasive animal models reproduced the true patho-
physiology of native AVS. Moreover, none of these models
allowed the study of the evolution of either the early phases
of aortic valve disease or the potential prevention of pro-
gression to severe stages of the disease. In this study, we
report, for the first time, the development of AVS in a
rabbit model of atherosclerosis.
METHODS
Animals. Twenty-two male New Zealand White rabbits
(weight 2 to 2.5 kg) were divided in three study groups (6 to
10 animals per group): 1) controls receiving normal rabbit
chow without any dietary supplement; 2) animals fed with
0.5% cholesterol-enriched chow (Harlan, Indianapolis, In-
diana); and 3) animals fed with 0.5% cholesterol-enriched
chow plus 50,000 IU/day vitamin D2 (Sigma; Markham,
Ontario, Canada) in drinking water. Vitamin D2 has been
shown by others to accelerate the atherosclerotic process in
this animal model. All animals were treated in accordance
with the recommendations of the Canadian Council for
Animal Care. The protocol was approved by the Universite´
Laval Animal Protection Committee.
Blood samples were taken through the marginal vein of
the ear at baseline and weekly thereafter for the measure-
ment of cholesterol as well as calcium levels in serum.
Echocardiography. Echocardiography was performed at
baseline and 12 weeks after the beginning of treatment.
Animals were sedated with an intramuscular injection of
ketamine (30 mg/kg), midazolam (0.5 mg/kg), and butor-
phanol (0.5 mg/kg). Ultrasound images were obtained with
a 12-MHz phased-array probe connected to a Sonos 5500
echograph (Philips Medical Imaging, Andover, Massachu-
setts).
From the Groupe de Recherche en Valvulopathies, Institut de Cardiologie de
Que´bec, Centre de Recherche Hoˆpital Laval, Universite´ Laval, Quebec, Canada. This
work was supported by grants from the Heart and Stroke Foundation of Canada
(Quebec) and the Institut de Cardiologie de Que´bec, to Drs. Arsenault and Couet.
Dr. Arsenault is a scholar from the Fonds de la Recherche en Sante´ du Que´bec. Dr.
Couet is a scholar from the Medical Research Council of Canada and the Cancer
Research Society, Inc.
Manuscript received October 8, 2002; revised manuscript received December 9,
2002, accepted December 26, 2002.
Journal of the American College of Cardiology Vol. 41, No. 7, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. doi:10.1016/S0735-1097(03)00090-1
The aortic valve area (AVA) was measured by the
standard continuity equation, as currently recommended in
the literature, in the same manner that is performed in
humans with suspected AVS. A parasternal long-axis view
was used to measure the diameter of the left ventricular
outflow tract and to observe the morphology and opening of
the aortic valve. The aortic valve was also imaged in the
short-axis view to assess leaflet morphology. An apical
five-chamber view was obtained to measure the stroke
volume with pulsed-wave Doppler proximal to the aortic
valve, as is routinely done in humans. Continuous-wave
Doppler was used to record the maximal and mean aortic
transvalvular gradients and to obtain the integral of trans-
valvular flow to be used in the continuity equation for AVA
calculation. The AVA was indexed to the animal’s body
weight.
All echocardiographic imaging and analyses were per-
formed throughout the protocol by the same investigator
experienced in performing echocardiographic studies in
rabbits and other small animals. Inter- and intra-observer
variability was assessed blindly for half of the animal studies
for AVA measurement.
Histology. At the end of the protocol, the ascending aortic
section containing the aortic valve was dissected, rinsed in
phosphate-buffered saline, embedded in Tissue-Tek
O.C.T. compound (Sakura Finetek, Torrance, California),
and snap-frozen in liquid nitrogen. Cross-sectional serial
sections were prepared, and alizarin red S and von Kossa’s
silver stains were employed to visualize calcium deposition.
Statistics. The results are presented as the mean value 
SEM. Repeated-measures one-way analysis of variance with
the post hoc Tukey’s test or paired t test was used for
intragroup comparisons to assess the evolution of Ca2
serum levels over time. The unpaired t test was used for
intergroup comparisons (total cholesterol levels). The paired
t test was used for comparisons of the effect of diet on
echocardiographic parameters. Statistical significance was
set at p  0.05.
RESULTS
Cholesterol and calcium levels (Fig. 1). Animals in
group 1 displayed no modifications of those two parameters.
Total cholesterol circulatory levels rose to high levels in both
groups 2 and 3 (Fig. 1A). Interestingly, vitamin D2 caused
an additional increase in serum cholesterol despite similar
cholesterol intake. Calcium levels were slightly more ele-
vated for the animals in group 3. This mild difference
reached statistical significance at week 8, although calcium
levels were elevated throughout the protocol (Fig. 1B).
Development of atherosclerosis. The arteries of the con-
trol group remained normal. As expected, and based on
previous observations by others, the animals fed with the
cholesterol-enriched diets (groups 2 and 3) developed severe
atherosclerotic involvement of their arteries, which was
evident on macroscopic as well as microscopic examination
(not shown).
Aortic valve (Figs. 2 to 6). Baseline AVAs were compa-
rable in all three groups. When corrected for body weight,
no significant change was noted in the animals in the
control and cholesterol groups (Fig. 2, middle column).
However, the animals in the cholesterol plus vitamin D2
group behaved differently (Fig. 2, bottom row). The AVA
decreased in eight of 10 animals after 12 weeks of treatment,
and the transvalvular gradients also increased in eight
animals. This decrease was even more pronounced when
Abbreviations and Acronyms
AVA  aortic valve area
AVS  aortic valve stenosis
Figure 1. Total cholesterol (A) and Ca2 (B) circulatory levels in hyper-
cholesterolemic rabbits receiving (open circles) or not receiving (solid
circles) daily supplements of vitamin D2. Results are expressed as the mean
value  SEM in mmol/l (n  8). The hatched region in part B
corresponds to the mean (line) 2 SD of serum calcium concentrations in
normal rabbits (n  18).
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AVA was indexed for the animal’s weight. The transvalvular
gradients remained normal in the control and cholesterol-
fed groups, but increased significantly in the cholesterol plus
vitamin D2 group, as AVA decreased (Fig. 3).
Overall, AVA decreased by 36%, the maximal gradient
increased by 300%, and the mean gradient increased by
107% (all p  0.05). Two-dimensional imaging of those
valves showed an increase in the thickness and echogenicity
of the leaflets and a reduced mobility compatible with leaflet
sclerosis and areas of calcification. This is confirmed by
visual inspection of excised valves (Fig. 4). Histologic
examination demonstrated leaflet thickening and calcium
deposition both at the aortic attachment site and in the
leaflet itself (Fig. 6). Calcifications were more prominent at
Figure 2. Effects of hypercholesterolemia in rabbits receiving (Cholvit D2) or not receiving (Chol) daily supplements of vitamin D2 on aortic valve
function, as assessed by echocardiography. The aortic valve area (AVA) (left column), indexed AVA (arbitrary units [AU]) (middle column), and maximal
gradient (mm Hg) (right column) were calculated as described in the Methods section and are represented for each individual rabbit. ns  not significant.
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the attachment site and the base of the leaflets. Histologic
evidence of calcium deposition is displayed in Figure 6.
Inter- and intra-observer variability was blindly assessed in
half of the animals for the echocardiographic measurement
of AVA by the continuity equation. Intra-observer variabil-
ity was 5%, and inter-observer variability was 8%.
DISCUSSION
The theory of atherosclerotic pathogenesis of AVS in
humans is becoming more and more popular. Aortic valve
stenosis had been described many years ago in patients
suffering from cholesterol metabolism abnormalities, such as
Tangier’s disease and severe homozygous familial hypercho-
lesterolemia (7–9). Following this lead, several recent pub-
lications have demonstrated a clear statistical link between
AVS, per se, and specific cardiovascular risk factors, such as
hypercholesterolemia, systemic hypertension, and diabetes
mellitus (1,2,4,6,10–13). Unfortunately, most of the evi-
dence currently available relies on observational cohort
studies. Prospective studies are clearly needed to assess the
effect of those risk factors, as well as the potential effect of
pharmacologic treatment, on the evolution of AVS.
In this study, we have been able to induce peripheral
atherosclerosis and, more importantly, AVS in animals fed
with a cholesterol-rich diet supplemented with vitamin D2.
Aortic valve leaflet thickening and reduced systolic motion
of those leaflets were clearly identified by echocardiography.
Transvalvular gradients increased significantly compared
with controls, and most importantly, the aortic valve open-
ing was significantly reduced at echocardiographic exami-
nation (two-dimensional and calculated AVA).
To our knowledge, this is the first description of a clear
prospective link between atherosclerosis and AVS in an
animal model. Previous studies have demonstrated athero-
sclerotic involvement of the aortic valve in hypercholester-
olemic animal models (14–19). Unfortunately, an in vivo
evaluation for detecting a potential stenosis of the valve was
never investigated in those animals.
As for atherosclerotic plaques, the mechanisms of aortic
valve calcification that contribute to the progressive stenosis
of the valve are still incompletely understood. In this
protocol, we used vitamin D supplementation in combina-
tion with a hypercholesterolemic diet, a supplementation
that has been used for decades by investigators studying
Figure 3. Two-dimensional imaging of the aortic valve by echocardiography. The valves were imaged in the parasternal long-axis (left panels) and
short-axis (right panels) views. In control animals (control), the aortic valve is a thin, barely visible structure. In cholesterol-fed animals with vitamin D
(CholVit D2), the aortic leaflets become thickened and hyperechogenic. The valve area is reduced, as shown by the decreased opening of the valve in
systole. Valve opening was traced over this echocardiographic image only as a visual aid to the reader and was not used to calculate aortic valve area.
Figure 4. Aortic valve photographs from rabbits fed with normal chow (left) or cholesterol plus vitamin D2 (right). The whole aortic valve is shown attached
to the aortic annulus, with a small portion of the ascending aorta. The reduced opening (center) can be readily assessed.
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rabbit models of atherosclerosis to enhance and accelerate
the development of the calcification process (20–23). Vita-
min D metabolites have been shown to induce a disruption
in the integrity of the arterial wall and some degree of
smooth muscle necrosis of the arterial media of swine and
rabbits, thereby enhancing the integration of lipid particles
by the arterial wall (24,25). This mechanism may explain
the accelerating effect of vitamin D on atherosclerosis
development in hypercholesterolemic rabbits. Conversely,
calcium channel blockers have been proven to delay the
development of atherosclerosis in hypercholesterolemic rab-
bits (20). We hypothesized that the aortic valve leaflets
would demonstrate the same behavior when subjected to
hypercholesterolemia and vitamin D supplementation and
that animals treated with this combination would develop
more severe aortic valve abnormalities earlier than those
treated with a high-cholesterol diet alone. Our results
confirm this hypothesis. Indeed, animals not receiving
supplements of vitamin D2 did not display any significant
degree of AVS after 12 weeks of treatment, despite very
high levels of blood cholesterol (20 mmol/l) and the
presence of peripheral atherosclerotic lesions. Unexpectedly,
animals receiving vitamin D had significantly higher cho-
lesterol levels than those not receiving it. The reason for this
remains unclear. However, because both groups of animals
received a similar amount of cholesterol supplements in
their food, we suspect that cholesterol absorption was
increased in the vitamin D group or that cholesterol
metabolism was influenced by vitamin D. We cannot
actually confirm whether vitamin D itself played a direct
role in the development of aortic stenosis in our animals or
whether it simply amplified the effects of hypercholesterol-
emia. The role of vitamin D in our model remains to be
explored. In humans, vitamin D overload has been mostly
associated with supra-valvular AVS, which was seen in our
animals in whom the level of stenosis was at the aortic valve
itself (26–28). Interestingly, a recent observation linked a
vitamin D receptor gene polymorphism to calcific aortic
stenosis in humans (29).
Our model offers many advantages over most of those
previously published. Pressure-overload animal models with
banding of the ascending aorta have been used to mimic the
situation seen in AVS (30–33). However, this model has
the disadvantage of producing a supra-coronary obstruction
that is not reflective of the situation of valvular stenosis, in
which the obstruction is proximal to the implantation of the
coronary arteries. In larger animals such as sheep, AVS has
also been induced by surgical procedures. Because the
disease is artificially created, it is impossible to study the
physiopathology of the disease on the valve and potential
strategies for preventing or slowing the degenerative pro-
cess. We describe a model in which the pathogenesis of
AVS is probably related to the same atherogenic factors that
also seem to be implicated in human disease. All animal
models have their limitations, and, of course, we are aware
that the animals in this protocol were submitted to extreme
conditions of hypercholesterolemia combined with vitamin
D supplementation, a combination that will never be
encountered in humans. Multiple risk factors that are clearly
absent from our model interact in humans to induce AVS.
The long-term evolution of our animal model has not been
assessed, and we still do not know if the disease will
continue to progress over time. Neither the reversibility nor
the effect of withdrawing the offending factors has been
assessed.
Conclusions. We report an experimental model of ac-
quired AVS in rabbits fed with a high-cholesterol diet and
supplements of vitamin D2. These results support the
hypothesis of the link between atherosclerosis and AVS in
humans. This experimental model may prove useful in
studying the early evolution of the disease, so the effects of
various atherosclerotic risk factors on this evolution and the
use of pharmacologic treatments to delay or even stop the
evolution.
Figure 5. Transvalvular aortic gradients in control (top panel) and cho-
lesterol plus vitamin D2 animals (bottom panel) by continuous-wave
Doppler imaging.
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